						<p class="boxed blue">ABILIFY<sup>&reg;</sup> (aripiprazole) is indicated for use as an adjunctive therapy to antidepressants in adults with Major Depressive Disorder who have had an inadequate response to antidepressant therapy.</p>
						<h6>Adding <a href="#">ABILIFY<sup>&reg;</sup></a> in patients with MDD may help improve functioning<sup>1-3</sup></h6>
						<img src="http://placehold.it/784x500" style="margin-bottom:3em;">
						<ul class="content eighty-percent">
							<li>Significant improvement in mean Sheehan Disability Scale (SDS) Score in 1 of 2 registrational studies<sup>1,2</sup>
								<ul>
									<li>In a third study, adjunctive ABILIFY did not separate from adjunctive placebo<sup>3</sup></li>
								</ul>
							</li>
							<li>Major depression was found to be associated with functional impairment as measured by SDS, a self-rated scale measuring impact of depression in work/school, family life/home responsibilities, and social domains</li>
							<li>SDS measures the impact of depression on functioning in the following domains:</li>
						</ul>
						<img src="http://placehold.it/784x400">
						<h5>Important Warning for Neuroleptic Malignant Syndrome (NMS)</h5>
						<p style="margin-bottom:3em;">As with all antipsychotic medications, a rare and potentially fatal condition known as Neuroleptic Malignant Syndrome (NMS) has been reported with ABILIFY. Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems.</p>
			
						<?php include '../inc/isi.php'; ?>

						<section class="references container" id="references">
							<p><strong>References:</strong></p>
							<ol class="reference">
								<li>Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. <em>J Clin Psychiatry</em>. 2007;68(6):843-853.</li>
								<li>Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. <em>J Clin Psychopharmacol</em>. 2008;28(2):156-165.</li>
								<li>Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. <em>CNS Spectr</em>. 2009;14(4):197-206.</li>
							</ol>
						</section>